{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SoC&page=39", "query": { "intervention": "SoC", "page": 39 }, "page_size": 10 }, "pagination": { "page": 39, "page_size": 10, "total_count": 1403, "total_pages": 141, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SoC&page=40&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SoC&page=38&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T17:49:52.989Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01354210", "title": "Text Messaging Intervention to Improve ART Adherence Among HIV-positive Youth", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Patient Adherence", "HIV" ], "interventions": [ { "name": "SMS Text Message Reminder", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Ann & Robert H Lurie Children's Hospital of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "29 Years", "sex": "ALL", "summary": "16 Years to 29 Years" }, "enrollment_count": 110, "start_date": "2010-10", "completion_date": "2014-02", "has_results": false, "last_update_posted_date": "2021-11-15", "last_synced_at": "2026-10-30T17:49:52.989Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01354210" }, { "nct_id": "NCT02355080", "title": "A Bundled Rapid HIV/HCV Testing Intervention to Increase Receipt of Test Results", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Substance-related Disorders" ], "interventions": [ { "name": "On-site bundled rapid HIV/HCV testing", "type": "BEHAVIORAL" }, { "name": "Standard of care (SOC)", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 134, "start_date": "2016-04", "completion_date": "2017-07", "has_results": false, "last_update_posted_date": "2018-02-23", "last_synced_at": "2026-10-30T17:49:52.989Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02355080" }, { "nct_id": "NCT07220616", "title": "A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematological Malignancies", "B-cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "DS3790a", "type": "DRUG" }, { "name": "Combination drug", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 420, "start_date": "2026-01-16", "completion_date": "2030-11-30", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-30T17:49:52.989Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07220616" }, { "nct_id": "NCT06453187", "title": "A Modified Platform Trial of Multiple CAMPs for the Management of Diabetic Foot Ulcers and Venous Leg Ulcers", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetic Foot Ulcer", "Venous Leg Ulcer" ], "interventions": [ { "name": "Urinary Bladder Matrix (UBM) sheet device for Venous Leg Ulcers", "type": "DEVICE" }, { "name": "Urinary Bladder Matrix (UBM) sheet device for Diabetic Foot Ulcers", "type": "DEVICE" }, { "name": "AmnioExcel Plus for Venous Leg Ulcers", "type": "DEVICE" }, { "name": "AmnioExcel Plus for Diabetic Foot Ulcers", "type": "DEVICE" }, { "name": "Standard of Care", "type": "PROCEDURE" } ], "intervention_types": [ "DEVICE", "PROCEDURE" ], "sponsor": "Integra LifeSciences Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 350, "start_date": "2024-11-18", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-10-30T17:49:52.989Z", "location_count": 13, "location_summary": "Los Angeles, California • San Francisco, California • Vista, California + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Vista", "state": "California" }, { "city": "Bridgeport", "state": "Connecticut" }, { "city": "Plant City", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06453187" }, { "nct_id": "NCT06972719", "title": "Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "BRCA1 Mutation", "BRCA2 Mutation" ], "interventions": [ { "name": "Experimental Arm", "type": "BEHAVIORAL" }, { "name": "SOC Arm", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "19 Years to 50 Years · Female only" }, "enrollment_count": 50, "start_date": "2025-09-30", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-10-30T17:49:52.989Z", "location_count": 2, "location_summary": "Chapel Hill, North Carolina • Durham, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06972719" }, { "nct_id": "NCT03287414", "title": "Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Idiopathic Pulmonary Fibrosis" ], "interventions": [ { "name": "VAY736", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Standard of Care (SoC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 30, "start_date": "2017-12-20", "completion_date": "2022-02-14", "has_results": true, "last_update_posted_date": "2024-06-18", "last_synced_at": "2026-10-30T17:49:52.989Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Aurora, Colorado • Miami, Florida + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03287414" }, { "nct_id": "NCT04189523", "title": "Does Early Administration of Ultrasound Guided Regional Anesthesia for Long Bone Fractures Effect Long Term Patient Opioid Usage", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Bone Fracture", "Opioid Use", "Opioid Dependence" ], "interventions": [ { "name": "SOC Pain Management", "type": "OTHER" }, { "name": "Early US Guided Nerve Block Administration", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Wayne State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2019-09-01", "completion_date": "2020-06", "has_results": false, "last_update_posted_date": "2019-12-12", "last_synced_at": "2026-10-30T17:49:52.989Z", "location_count": 2, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04189523" }, { "nct_id": "NCT05179824", "title": "Tempus Priority Study: A Pan-tumor Observational Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Prostate Cancer", "Bladder Cancer", "Lung Cancer", "Brain Cancer", "Pancreatic Cancer", "Ovarian Cancer", "Fallopian Tube Cancer", "Peritoneal Cancer", "Cancer of Liver", "Cancer of Colon", "Cancer of Head and Neck", "Cancer of Stomach", "Cancer of Gastrointestinal Tract", "Cancer of Rectum", "Cancer of Esophagus", "Cancer of Skin", "Cancer of Cervix", "Cancer of Kidney", "Cancer of Larynx", "Cancer of Endometrium", "Cancer of the Bile Duct", "Cancer of Vulva", "Cancer of Bone and Connective Tissue", "Leukemia", "Lymphoma", "Spinal Cord Cancer" ], "interventions": [ { "name": "Observation", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Tempus AI", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1000, "start_date": "2020-10-19", "completion_date": "2030-10-19", "has_results": false, "last_update_posted_date": "2025-05-06", "last_synced_at": "2026-10-30T17:49:52.989Z", "location_count": 2, "location_summary": "Dallas, Texas • Houston, Texas", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05179824" }, { "nct_id": "NCT07383441", "title": "Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Clear Cell Renal Cell Carcinoma", "Metastatic Clear Cell Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Axitinib", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Clostridium butyricum CBM 588 Probiotic Strain", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab and Recombinant Human Hyaluronidase", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo Administration", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 718, "start_date": "2026-06-05", "completion_date": "2034-01-31", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-30T17:49:52.989Z", "location_count": 41, "location_summary": "Fayetteville, Arkansas • Jonesboro, Arkansas • Rogers, Arkansas + 36 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Bloomington", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07383441" }, { "nct_id": "NCT06859424", "title": "A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "AML (Acute Myelogenous Leukemia)", "Acute Lymphoid Leukemia (ALL)", "Acute Leukemia (Category)", "MDS (Myelodysplastic Syndrome)", "CML (Chronic Myelogenous Leukemia)", "CLL (Chronic Lymphocytic Leukemia)", "Prolymphocyctic Leukemia", "Chronic Myelomonocytic Leukemia (CMML)", "Myeloproliferative Neoplasm (MPN)", "Lymphoma", "Myelofibrosis" ], "interventions": [ { "name": "Conditioning Regimen A", "type": "DRUG" }, { "name": "Conditioning Regimen B", "type": "DRUG" }, { "name": "Conditioning Regimen C", "type": "DRUG" }, { "name": "Conditioning Regimen D", "type": "DRUG" }, { "name": "Conditioning Regimen E", "type": "DRUG" }, { "name": "Hematopoietic Cell Transplantation", "type": "PROCEDURE" }, { "name": "PTCy (50 mg/kg D3, D4)", "type": "DRUG" }, { "name": "PTCy (25 mg/kg D3, D4)", "type": "DRUG" }, { "name": "Post-transplant Tacrolimus", "type": "DRUG" }, { "name": "Post-transplant Mycophenolate mofetil", "type": "DRUG" }, { "name": "Post-transplant Abatacept", "type": "DRUG" }, { "name": "Post-transplant Ruxolitinib", "type": "DRUG" }, { "name": "Supportive Care: Growth Factors", "type": "DRUG" }, { "name": "Supportive Care: Blood Products", "type": "PROCEDURE" }, { "name": "Supportive Care: Infection Prophylaxis", "type": "OTHER" }, { "name": "Supportive Care: Intravenous immune globulin (IVIG)", "type": "OTHER" }, { "name": "Supportive Care: Seizure prophylaxis", "type": "DRUG" }, { "name": "Supportive Care: Monitoring and management of CRS", "type": "OTHER" }, { "name": "Supportive Care: Prophylaxis against infections", "type": "OTHER" }, { "name": "Supportive Care: Prophylaxis against infections", "type": "DRUG" }, { "name": "Supportive Care: Lipid elevations", "type": "OTHER" }, { "name": "Study treatment compliance", "type": "OTHER" }, { "name": "Prohibited Concomitant Therapy", "type": "OTHER" }, { "name": "Permitted Concomitant Therapy", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Center for International Blood and Marrow Transplant Research", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "66 Years", "sex": "ALL", "summary": "18 Years to 66 Years" }, "enrollment_count": 358, "start_date": "2025-07-25", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-10-30T17:49:52.989Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06859424" } ] }